CTN Translation & Implementation SIG |
|
 The NIDA Clinical Trials Network (CTN) Translation & Implementation (T&I) Special Interest Group (SIG) was launched in February 2021. This SIG brings together a large group of individuals across and beyond the CTN who have an interest in leveraging dissemination & implementation (D&I) science in addiction treatment research.
The goal is to enhance the CTN platform by examining implementation factors in clinical trials and to improve the equitable sustainment of CTN-studied interventions that have proven to be effective. The SIG also features 4 workgroups with specific areas of focus: Implementation Outcomes, Health Equity, Implementation Strategies, and Early Career Investigators.
A new page on the CTN Dissemination Library website about the SIG features information about the SIG, contact information for joining the group or workgroups, and links to recordings from their Speaker Series.
Their first Speaker Series webinar, from May 2021, featured Jeffrey De Flavio, MD, speaking on Scaling Innovative Clinical Models, and you can find the recording here.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
CTN Youth SIG
 Join the CTN Youth SIG on November 19, 2021 (11am-12pm ET) for their next webinar: Measuring and Improving the Quality of Opioid Prescribing to Children and Young Adults.
The SIG has invited Kao-Ping Chua, MA, PhD (U. Michigan Medical School) to speak about opioid prescribing patterns that are associated with adverse events (overdose, e.g.) in youth, the prevalence and safety of opioid prescribing to youth, and ongoing efforts to reduce excessive opioid prescribing after surgery in children and young adults.
Read more about the webinar | Connect to the webinar
|
CTN Trial Progress
 Randomizations for Active Studies as of the November 14 trial Progress Report.
CTN-0060-A-1 - Enrolled 721
CTN-0079-A-1 - Enrolled 43
CTN-0080 - Enrolled 72
CTN-0097 - Enrolled 206
CTN-0098 - Enrolled 9
CTN-0099 - Enrolled 744
CTN-0099-A-1 - Enrolled 85
CTN-0100
Discontinuation - Enrolled 24
Retention - Enrolled 114
CTN-0101 - Enrolled 87
|
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
New in the CTN Dissemination Library
Two-page factsheet about CTN-0051:
Economic Evaluation of Extended-Release Injectable Naltrexone Compared to Buprenorphine-Naloxone Initiated in Inpatient Settings for Treatment of Opioid Use Disorder: Results Derived from the X:BOT Clinical Trial. Murphy SM, et al. Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH), May 2021.
Journal articles:
Research Priorities for Expanding Access to Methadone Treatment for Opioid Use Disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report. Joudrey PJ, et al. Substance Abuse 2021;42(3):245-254.
Longitudinal Study of Impact of Medication for Opioid Use Disorder on Hamilton Depression Rating Scale. Wang K, et al. Journal of Affective Disorders 2021 (in press). CTN-0051
Is Extended Release Naltrexone Superior to Buprenorphine-Naloxone to Reduce Drinking Among Outpatients Receiving Treatment for Opioid Use Disorder? A Secondary Analysis of the CTN X:BOT Trial. Roache JD, et al. Alcoholism: Clinical and Experimental Research 2021 (in press). CTN-0051
Perspectives on Extended-Release Naltrexone Induction Among Patients Living with HIV and Opioid Use Disorder: A Qualitative Analysis. Hoffman KA, et al. Addiction Science & Clinical Practice 2021;16:67. CTN-0055
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
News from the Nodes
Western States
 Last month's webinar from the Western States Node and the Northwest and Pacific Southwest ATTCs was a huge success, with over 675 attendees!
The session, led by John Kelly, PhD, ABPP of Harvard University, was about Attitudes & Stigma Around Addiction, and provided a detailed look at the fundamental causes of stigma and discrimination in relation to substance use disorder, as well as a review of some of the paradoxical findings from the latest research.
The goal of this joint series from the CTN and ATTC is to help scholars and clinicians in the addiction field stay abreast of cutting edge science.
Watch for more in this series coming in 2022!
Find the recording and slides here! |
Protocol Updates
CTN-0077
 Tessa Matson, MPH, Health Systems node investigator, led a cross-sectional study of 185,565 primary care patients to estimate the prevalence of electronic health record (EHR) documentation of medical cannabis use and health conditions for which cannabis use might have benefits and risks.
She and colleagues found that 2% of patients had medical cannabis use documented in their EHRs. Among patients with EHR documented medical cannabis use, more had health conditions for which cannabis use might confer risks (55%) compared to health conditions for which cannabis use might confer benefits (45%). Ms. Matson’s analysis was published in the May 6 issue of JAMA Network Open (free full-text) and highlighted here.
Her publication resulted in an invited commentary in the September 15 issue of JAMA Network Open on the self-reported practices of frontline cannabis dispensary works and the implications for clinicians. |
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
Postdoctoral Traineeship in Substance Use Disorders Treatment and Services, UCSF
The University of California, San Francisco is currently accepting applications to its NIDA-funded two-year postdoctoral research training program in substance use treatment and services research. The training program is supported in part by the Western States Node of the NIDA Clinical Trials Network. Resources from other significant extramural funding and R01-level grants are also routinely available to scholars.
The program is one of the few that trains scientists in treatment and services research. Scholars work with a preceptor to design and implement studies on treatment of substance use disorders (SUD), including nicotine, cannabis, opioids, and other substances. Scholars also select a specific area of focus for independent research.
Current research interests of faculty include trials of efficacy and effectiveness of psychosocial and pharmacologic treatment of substance use disorders, and a variety of university-affiliated and community substance use treatment programs are available as research sites.
More information can be found at:
https://psychiatry.ucsf.edu/SUDTSR/ and https://psychiatry.ucsf.edu/SUDTSR/faq
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
New from the ATTC Network
|
Also of Interest
|
   
|
